Research programme: facioscapulohumeral muscular dystrophy therapeutics - Evotec AG/Facio TherapiesAlternative Names: Facioscapulohumeral muscular dystrophy therapeutics - Evotec AG/Facio Therapies; FSHD therapeutics - Evotec AG/Facio Therapies
Latest Information Update: 14 May 2015
At a glance
- Originator Evotec AG; Facio Therapies
- Class Small molecules
- Mechanism of Action DUX4 protein inhibitors; SMCHD1 protein stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Facioscapulohumeral muscular dystrophy